The breast cancer cohort of the MEDIOLA study (open-label, multicenter, phase I/II) explored the efficacy of PARP inhibitor olaparib combined with durvalumab in advanced BRCA-mutated HER2-negative metastatic breast cancer, and the results showed that the ORR reached 63.3%, and the PFS and OS were 8.2 months and 21.5 months, respectively (45). The gene discussed is ERBB2; the disease is breast carcinoma.